Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

DHT is not the only cause of male pattern hair loss; genetic sensitivity, inflammation, and fibrosis also contribute. GHK-Cu, a copper peptide, is being explored as an alternative treatment to finasteride and minoxidil, showing potential in improving follicle health.

Switching from finasteride to dutasteride and oral minoxidil led to thicker hair and reduced hairline recession. Occasional flushing from minoxidil will be managed by lowering the dose.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.

Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.

Hair loss treatments that avoid significantly lowering systemic DHT levels, focusing on topical options like dutasteride mesotherapy, minoxidil, and ketoconazole. The user is exploring alternatives like KX-826 and RU58841 due to concerns about hormone levels.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Switching from finasteride to dutasteride can cause initial shedding, but many see long-term hair regrowth and stabilization. Responses vary, with some experiencing fewer side effects and others finding it less effective.

The conversation discusses various hair growth treatments, including topical and oral minoxidil, microneedling, LLLT, PRP, exosomes, latanoprost, copper peptides, and upcoming treatments like PP405 and Vdphl01. It also covers managing side effects of minoxidil, such as dry scalp, and mentions the use of dutasteride and finasteride for hair loss.

Hair loss treatments have not advanced since 2018, with finasteride, minoxidil, and RU58841 still being the main options. A permanent cure is unlikely due to the profitability of ongoing treatments.

The user had a hair transplant and uses oral minoxidil, a red laser therapy helmet, fish oil, collagen, and sardines for hair thinning but avoids finasteride due to side effect concerns. Many suggest these methods may not be effective long-term without a DHT blocker.

The user is considering stopping finasteride due to depression, anxiety, and difficulty building muscle, despite its effectiveness in stopping hair loss. Suggestions include reducing the dose, switching to topical solutions, or consulting a doctor for alternatives like dutasteride or RU58841.

The conversation discusses hair loss and its potential link to caffeine consumption, with the original poster experiencing increased shedding after consuming more coffee. They mention being a non-responder to finasteride and plan to reduce coffee intake, while others suggest various factors like stress, physical exertion, and medication changes could also contribute to hair loss.

Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

A 24-year-old shared their 7-month progress using a topical solution of finasteride 0.1%, minoxidil 5%, and hydrocortisone butyrate 0.08%, along with ketoconazole shampoo, to treat hair loss, reporting no side effects and noticeable hair improvement. They also take vitamin D and biotin supplements, use a dermastamp, and manage Hashimoto's without thyroid medication.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

Low-dose Dutasteride, used 2-3 times a week, is as effective as daily Finasteride for hair loss with fewer side effects. Users report increased libido and better results with Dutasteride compared to Finasteride.

A pharmacy student proposed a hair loss treatment using minoxidil, finasteride, clascoterone, and tretinoin, aiming for high effectiveness with minimal side effects. Reactions were mixed, with some questioning its feasibility and others showing interest.

Dutasteride is more effective than finasteride for hair loss, with optimal dosing at 0.5mg once or twice a week to minimize side effects. Topical application may further reduce side effects while effectively lowering scalp DHT.

A serum with oleic and palmitoleic acids shows promise for hair regrowth in mice, but its effectiveness in humans is unproven. Minoxidil and finasteride remain the recommended treatments.

Minoxidil sulfate is considered for those unresponsive to regular minoxidil, with some trying a 10% formulation from Folligenz. Concerns exist about the product's stability and transparency, but some users report positive initial results.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

Insulin resistance may increase DHT production, contributing to hair loss, and addressing it through diet, nutrients, and natural DHT blockers like saw palmetto and pumpkin seed oil could help reverse hair loss. Some users prefer medications like finasteride for more effective results.

PP405 is discussed as a potential hair loss treatment, with doubts about its effectiveness and availability. Users mention using finasteride and minoxidil, and express concerns about PP405's cost and market release.

Finasteride and minoxidil use resulted in a more youthful appearance and improved skin. There is debate about their effects on collagen and skin aging, with no solid evidence supporting significant changes due to finasteride.

Finasteride and dutasteride can cause psychiatric side effects like depression and suicidal thoughts in some users, especially those with a history of mental health issues. While some users experience positive hair growth results, others face severe psychological effects, raising concerns about their safety and the need for careful monitoring.

Some users experienced erectile dysfunction with finasteride but not with dutasteride, while others had issues with both. Individual reactions vary, with some reporting improved mood and hair growth on dutasteride.